In staggering setback, toxic reaction kills Cellectis’ first CAR-T patient, forcing trial halt
The FDA has forced Cellectis $CLLS to slam the brakes on two clinical trials of its off-the-shelf version of a CAR-T therapy after their first …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
